Dr Oliver Hulson discusses an advanced AI software system being piloted in Leeds to help improve prostate cancer diagnosis ...

A large screening trial showed that using prostate-specific antigen density (PSAD) before MRI prevented overdiagnosis and lowered resource use while preserving the detection of clinically significant ...

Mordor Intelligence has published a new report on the prostate cancer market, offering a comprehensive analysis of trends, growth drivers, and future projections.

In the phase 3 EMBARK trial, enzalutamide plus leuprolide and enzalutamide monotherapy were associated with longer metastasis-free survival than leuprolide alone among patients with biochemically ...

Prostate cancer is the most commonly diagnosed cancer among men in the United Kingdom. Because of this, many men look for ...

Pfizer is eyeing an earlier use of its PARP inhibitor Talzenna after a positive phase 3 trial in metastatic hormone-sensitive prostate cancer (mHSPC). The phase 3 Talapro-3 trial met its primary ...